Scholarlink

<p>Single-cell multi-omics technologies profile multiple molecular layers in individual cells, but existing methods often struggle to integrate transcriptomic, proteomic, and epigenomic measurements into an interpretable representation while preserving relationships among cells. Here, we present the single-cell multi-omics adversarial graph convolutional autoencoder (scMAGCA), which constructs cell graphs and uses adversarial alignment to learn interpretable shared embeddings that capture cellular heterogeneity and regulatory complexity. Across diverse datasets, scMAGCA outperforms existing methods in modality alignment, clustering, and batch correction. In Alzheimer’s disease, scMAGCA resolves neuronal subtypes and regulatory programs that are missed by single-modality analyses. In kidney cancer, it identifies tumor-specific epithelial and endothelial populations and uncovers biomarkers validated by quantitative polymerase chain reaction. These results support scMAGCA as an interpretable framework for resolving complex cell states in disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interpretable modality-aware mapping of gene regulation in single-cell multiomics with scMAGCA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Yunhe Wang,
  • Zeming Zhou,
  • Wei Liu,
  • Peiru Zhang,
  • Yue Cheng,
  • Yanchi Su,
  • Fuzhou Wang,
  • Ka-Chun Wong,
  • Xiangtao Li

摘要

Single-cell multi-omics technologies profile multiple molecular layers in individual cells, but existing methods often struggle to integrate transcriptomic, proteomic, and epigenomic measurements into an interpretable representation while preserving relationships among cells. Here, we present the single-cell multi-omics adversarial graph convolutional autoencoder (scMAGCA), which constructs cell graphs and uses adversarial alignment to learn interpretable shared embeddings that capture cellular heterogeneity and regulatory complexity. Across diverse datasets, scMAGCA outperforms existing methods in modality alignment, clustering, and batch correction. In Alzheimer’s disease, scMAGCA resolves neuronal subtypes and regulatory programs that are missed by single-modality analyses. In kidney cancer, it identifies tumor-specific epithelial and endothelial populations and uncovers biomarkers validated by quantitative polymerase chain reaction. These results support scMAGCA as an interpretable framework for resolving complex cell states in disease.